Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 20;195(45):E1546-E1547.
doi: 10.1503/cmaj.230820.

Novel obesity treatments

Shohinee Sarma  1 , Susan Tran  2 , Michael Fralick  2
Affiliations

Novel obesity treatments

Shohinee Sarma et al. CMAJ. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Shohinee Sarma reports support from the Clinician Investigator Program and the Clinician Scientist Training Program at the University of Toronto, and has received honoraria for presentations from the American Diabetes Association. Susan Tran reports honoraria from Novo Nordisk for content unrelated to obesity treatments. Michael Fralick was a consultant for ProofDx, a start-up company creating a point-of-care device for COVID-19 using CRISPR. and is an advisor for SIGNAL1, a start-up company that implements machine-learned solutions into clinical practice. No other competing interests were declared.

References

    1. Wadden TA, Bailey TS, Billings LK, et al. STEP 3 Investigators. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 2021;325:1403–13. - PMC - PubMed
    1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205–16. - PubMed
    1. Tuttle KR, Lakshmanan MC, Rayner B, et al. . Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018;6:605–17. - PubMed
    1. Highlights of prescribing information: Wegovy. Silver Spring (MD): US Food and Drug Administration; 2017. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf (accessed 2023 Sept. 1).
    1. Bezin J, Gouverneur A, Pénichon M, et al. . GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care 2023;46:384–90. - PubMed